Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
Read More
Section: Sales
Novartis to acquire Excellergy in deal worth up to $2bn
Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases
Read More
Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment
The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study
Read More
GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension
PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide
Read More
Lilly announces acquisition of Ventyx Biosciences for around $1.2bn
Multiple Ventyx drugs are currently in phase 2 development for inflammatory disease
Read More